Department of Neurosurgery, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
College of Medicine, Drexel University, Philadelphia, Pennsylvania, USA.
World Neurosurg. 2022 Nov;167:e70-e78. doi: 10.1016/j.wneu.2022.07.147. Epub 2022 Aug 7.
Neuromodulatory implants provide promising alternatives for patients with drug-resistant epilepsy (DRE) in whom resective or ablative surgery is not an option. Responsive neurostimulation (RNS) operates a unique "closed-loop" system of electrocorticography-triggered stimulation for seizure control. A comprehensive review of the current literature would be valuable to guide clinical decision-making regarding RNS.
Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocols, a systematic PubMed literature review was performed to identify appropriate studies involving patients undergoing RNS for DRE. Full texts of included studies were analyzed and extracted data regarding demographics, seizure reduction rate, responder rate (defined as patients with >50% seizure reduction), and complications were compiled for comprehensive statistical analysis.
A total of 313 studies were screened, and 17 studies were included in the final review, representative of 541 patients. Mean seizure reduction rate was 68% (95% confidence interval 61%-76%), and the mean responder rate was 68% (95% confidence interval 60%-75%). Complications occurred in 102 of 541 patients, for a complication rate of 18.9%. A strong publication bias toward greater seizure reduction rate and increased responder rate was demonstrated among included literature.
A meta-analysis of recent RNS for DRE literature demonstrates seizure reduction and responder rates comparable with other neuromodulatory implants for epilepsy, demonstrating both the value of this intervention and the need for further research to delineate the optimal patient populations. This analysis also demonstrates a strong publication bias toward positive primary outcomes, highlighting the limitations of current literature. Currently, RNS data are optimistic for the treatment of DRE but should be interpreted cautiously.
神经调节植入物为药物难治性癫痫(DRE)患者提供了有前途的替代方案,这些患者不适合进行切除性或消融性手术。反应性神经刺激(RNS)采用电皮质图触发刺激的独特“闭环”系统来控制癫痫发作。对当前文献进行全面综述对于指导关于 RNS 的临床决策非常有价值。
根据系统评价和荟萃分析的首选报告项目协议,对 PubMed 文献进行了系统综述,以确定涉及接受 RNS 治疗 DRE 的患者的适当研究。对纳入研究的全文进行分析,并提取关于人口统计学、癫痫发作减少率、应答率(定义为癫痫发作减少>50%的患者)和并发症的数据,以进行综合统计分析。
共筛选了 313 项研究,最终有 17 项研究纳入了最终综述,代表了 541 名患者。平均癫痫发作减少率为 68%(95%置信区间 61%-76%),平均应答率为 68%(95%置信区间 60%-75%)。541 名患者中有 102 名发生了并发症,并发症发生率为 18.9%。纳入文献中显示出强烈的发表偏倚,倾向于更大的癫痫发作减少率和更高的应答率。
对最近关于 DRE 的 RNS 文献进行荟萃分析表明,癫痫发作减少率和应答率与其他用于治疗癫痫的神经调节植入物相当,这既证明了这种干预的价值,也需要进一步研究来确定最佳患者人群。这项分析还表明,对阳性主要结果存在强烈的发表偏倚,突出了当前文献的局限性。目前,RNS 数据对 DRE 的治疗结果较为乐观,但应谨慎解读。